Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 143   

Articles published

NVS 97.40 -1.76 (-1.77%)
price chart
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Large Inflow of Money Witnessed in Novartis AG (ADR) Shares  Rock Hill Daily
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Related articles »  
Novartis AG (ADR) (NVS)'s Cosentyx Gets Clearance In Europe
Novartis AG (ADR) (NYSE:NVS)'s Cosentyx� gets the European Commission approval to be the first-line treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy.
Stock Watch: Novartis AG (ADR) (NYSE:NVS), MGIC Investment Corp. (NYSE ...  Realist Investor
Novartis Gets European Approval For Potential Blockbuster Cosentyx  Bidness ETC
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
Novartis AG (ADR) Investors Book Profit on Strength  Bar and Graph Report
Brokerage Firm Price Target on Novartis AG (ADR)  Stafford Daily
First Call Rating Update on Novartis AG (ADR)
Novartis AG (ADR) (NYSE:NVS) has received a Buy rating from First Call in their declaration. The rating agency has disclosed the information in the equity research recommendation.
Investors Sell Novartis AG (ADR) on Price Strength  Wall Street Pulse
Bullish and Outperform S&P 500: Eldorado Gold Corp (USA) , Novartis AG (ADR)
Shares of Eldorado Gold Corp (USA) (NYSE:EGO) rose by 9.64% in the past week and 15.11% for the past 4 weeks. For the past week, the counter has outperformed the S&P 500 by 11.02% and the outperformance increases to 18.03% for the past 4 weeks.
Novartis AG (ADR) Analyst Rating Update
As many as 8 brokerage firms have rated Novartis AG (ADR) (NYSE:NVS) at 2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of Neutral.
Options Check-Up: Bristol-Myers Squibb, Merck & Co., and Novartis AG
Among the stocks attracting attention from options traders lately are pharmaceutical firms Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co.
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
Novartis AG (ADR) (NVS) Beats Analyst Estimates; Is Expected To Perform Well ...
On the deal between Novartis AG (ADR) (NYSE:NVS) and Google Inc. (NASDAQ:GOOGL), Rundquist said that the deal is interesting for both the companies and the deal represents a new way to thinking in healthcare, by combining bio-technology healthcare ...
Related articles »